Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients in need. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Zenas’ experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune diseases.
Investment Stage: Series B
Portfolio 3
| Date | Name | Website | Total Raised | Location |
| 08.01.2026 | STRM.BIO | strm.bio | $8M | United Sta... |
| 23.09.2025 | Ensoma | ensoma.com | $258M | United Sta... |
| 22.09.2025 | Avenzo The... | avenzotx.com | $210M | United Sta... |
Mentions in press and media 13
| Date | Title | Description |
| 31.01.2026 | TRexBio Secures $50M to Accelerate Treg-Targeted Immunotherapy Pipeline | TRexBio secured $50 million. This clinical-stage biotech develops precision immunoregulatory medicines. Its focus: tissue regulatory T cell (Treg) biology. Funding fuels clinical and preclinical pipeline advancement. Lead program TRB 061, a... |
| 28.01.2026 | TRexBio: $50 Million Raised To Advance Tissue-Targeted Treg Immunology Pipeline | TRex Bio, a clinical-stage biotechnology company focused on precision immunoregulatory medicines derived from tissue regulatory T cell biology, announced it closed an oversubscribed $50 million financing to support clinical and preclinical ... |
| 27.01.2026 | TRexBio Raises $50M in Funding | TRexBio, a San Francisco, CA-based clinical-stage biotechnology company, raised $50M in funding. Backers included new investors Janus Henderson Investors, Balyasny Asset Management L.P. and Affinity Asset Advisors, as well as existing inves... |
| 11.01.2026 | STRM.BIO Secures $8M Seed 2, Propelling Non-Viral Gene Therapy Revolution | STRM.BIO, a Cambridge biotech, closed an $8M Series Seed 2 round. It drives non-viral gene therapy innovation. Its MV platform delivers genetic medicines for in vivo cell engineering. Total recent funding hit $16.4M. Funds advance the pipel... |
| 08.01.2026 | STRM.BIO: $8 Million Series Seed 2 Closed To Advance Non-Viral Gene Delivery For In Vivo Cell Engineering And Gene Therapy | STRM.BIO raised $8 million in a Series Seed 2 financing to advance its non-viral gene delivery platform for in vivo cell engineering and gene therapy. The round included funding from Recordati, with continued participation from Boehringer I... |
| 07.01.2026 | STRM.BIO Raises $8M in Series Seed 2 Financing | STRM.BIO, a Cambridge, MA-based biotechnology company advancing non-viral delivery technologies for in vivo cell and gene therapy, raised $8M in Series Seed 2 financing. The round was led by Recordati with participation form Boehringer Inge... |
| 03.10.2025 | Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs | Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backe... |
| 23.09.2025 | Ensoma Raises $53M in Funding | Ensoma, a Boston, MA-based in vivo hematopoietic stem cell (HSC) engineering company, raised $53M in funding. Backers included Gilead (Nasdaq: GILD), which has also appointed an executive to the Ensoma board of directors as part of its inve... |
| 22.09.2025 | Avenzo Therapeutics Raised $60M in Series B Funding | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding. The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund,... |
| 23.11.2024 | TRexBio: $84 Million (Series B) Closed To Decode Human Tissue Immune Biology | TRex Bio – a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics – announced the closing of an oversubscribed $84 million Series B funding round. This funding was led by Delos Capital, with additi... |
Show more